Alan spent 31 years with Humana and served as President of the company’s Retail Segment, responsible for leading strategy, growth, clinical, network, and business operations. As a member of the management team, Alan contributed to Humana’s strategic direction, reporting directly to the chief executive officer. Throughout his 31-year-tenure with Humana, Alan served in several key leadership roles, including Vice President and Chief Financial Officer of Senior Products, Vice President of Medicare Service Operations and President of the East Region, one of the company’s key Medicare Advantage geographies.

Alan currently works as an operating advisor and executive advisor. He currently sits on various boards, including Sevita, Cano Health, GoHealth, Help at Home, and Evergreen Nephrology. Alan also served as chairman of the board for the National Senior Olympic Games, and on various non-profit boards.

Alan holds a Master’s of Business Administration with distinction from the University of Louisville and a Bachelor’s degree in Finance from the University of Kentucky.

Alex migrated to the United States in 2008, at a time when the U.S. healthcare industry started a massive transition and tectonic shifts. Fascinated with both the new complexity and with enormous opportunities to improve people’s lives, innovate, and create new business models, Alex knew he wanted to work in the healthcare industry.

Pursuing his passion, Alex joined healthcare practice at McKinsey & Co. and spent ten years learning intricacies of U.S. healthcare and serving all types of industry players – payers, providers, pharmacies, PBMs, and private equity funds investing in healthcare. After those years, Alex wanted to build transformative healthcare companies and joined Rubicon because he believed in the vision and mission laid out by founder, Adam Boehler.

Ben is an entrepreneur, biomedical engineer, and life sciences investor with a track record of founding and scaling startups in the medical device and biotech/CRO sectors. Most recently, he served as Chief Business Officer at AxoSim, where he led commercial and corporate strategy, built a sales organization serving global biopharma companies, licensed platforms from Johns Hopkins and Tulane, and spearheaded the acquisition of a publicly traded competitor. Prior to AxoSim, Ben founded Bioceptive straight out of Tulane University, where he invented a novel medical device and guided it through product development, multiple clinical trials, and ultimately FDA clearance. At Rubicon, Ben focuses on investment strategy within pharma services, with an emphasis on discovery CROs, CDMOs, and other key segments across the life sciences landscape.

Carol has over 35 years of experience in healthcare leadership, focusing the most recent 22 years on value-based care and home-based medical services. Most recently, Carol was the Chief Operating Officer and Co-Founder of Landmark and Co-Founder of Landmark Health, remaining with Landmark as they navigated the initial integration within Optum. Carol has led businesses in care management, in-home care delivery, and managing risk arrangements with vulnerable populations. As a career operator, she has overseen teams like field operations, clinical recruiting, new marketing implementation, call center operations, clinical IT systems and reporting, business development, and account management. Across her tenures at Care Level Management, Inspiris, Optum, and Landmark, Carol has implemented over 60 home- based primary care programs in 26 different states. When not working in healthcare, Carol is involved in working with her son on his podcast We the Children on climate disruption and solutions to the climate crisis, along with many other non-profit and volunteer organizations.

Dave Wichmann is currently Co-Founder of Jory Capital, a private equity fund focused on investing in transformative companies and management teams capable of developing the next generation of health and human performance.

Dave is the former chief executive officer of UnitedHealth Group, one of the world’s leading and most diverse healthcare companies. During his 23-year tenure, he served an instrumental role in the development of United’s distinctive market position as a diverse health benefits and services enterprise with a mission to serve the health needs of all people while helping make the health system work better for everyone. In turn, United grew to achieve distinctive financial performance and shareholder returns and, under Dave’s leadership, including during the pandemic, the company was twice recognized by its peers as an All-Star among Fortune’s Top 50 Most Admired Companies for the only time in the company’s history.

Prior to joining UnitedHealth Group, Dave was a partner at Arthur Andersen & Co.

Dave serves as a public company director of Boston Scientific and Privia and as a member of the Temasek Americas Advisory Panel. He previously served on the public company boards of UnitedHealth Group Incorporated and Tennant Company. Dave received his B.S. in accounting from Illinois State University.

David is the President and CEO of Unified Women’s Health and serves on the boards of several healthcare companies focused on provider services. He previously held the role of Global CEO at GenesisCare, an international oncology services provider operating across Australia, the U.S., the U.K., and Spain. His prior leadership roles include President & CEO of Physicians Endoscopy, a GI-focused investment and management services firm supporting independent providers; Chief Operating Officer of Privia Health; and Chief Financial Officer of Smile Brands. Earlier in his career, he held senior executive positions at McKesson Specialty Health and US Oncology.

Originally from Scotland, David earned a Bachelor of Arts with Honors in Accounting and an MBA from the University of Strathclyde in Glasgow. He is a Chartered Financial Analyst (CFA), Certified Public Accountant (CPA), Chartered Accountant (CA), and Corporate Treasurer.